MTOR and metastatic melanoma: Moreover, to validate the differential enrichment of the mTOR pathway, we analyzed the single-cell transcriptomes of CD8+ TILs from a new cohort of metastatic melanoma patients collected prior to anti-PD-1 immunotherapy.